

Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response.	J Med Virol	81	452-458	2009
Akuta N, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil	Intervirolgy	in press	in press	2009

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sekine-Osajima Y, <u>Nakagawa M</u> , Sakamoto N, Enomoto N, et al.	Two flavonoids extracts from a herb, <i>Glycyrrhizae radix</i> , inhibit <i>in-vitro</i> hepatitis C virus replication.	<i>Hepatology Res</i> ,	39	60-69	2009
Sakamoto N, <u>Nakagawa M</u> , Enomoto N, et al.	Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA.	<i>J J Gastro Hepatol</i>	23	1437-1447	2008
Sekine-Osajima Y, <u>Nakagawa M</u> , S akamoto N, Enom oto N, et al.	Development of plaque assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity.	<i>Virology</i>	371	71-85	2008

研究成果の刊行に関する一覧表レイアウト

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sermasathanasawadi R, Kato N, et al.	Association of IRF-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.	Liver Int	28	798-806	2008
Hua R, Kato N, et al.	Rapid detection of the hepatitis B virus YMDD mutant using TaqMan-minor groove binder probes.	Clinica Chemica Acta	395	151-154	2008
加藤直也, 他.	B 型慢性肝炎の抗ウイルス療法 抗ウイルス薬の将来	日本内科学会 雑誌	97 巻 1 号	50-56	2008

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表雑誌	巻	ページ	出版年
1) Kato N, (加藤)	Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture.	Archives of Virology	154	77-85	2009
2) Ariumi Y, (加藤)	The DNA damage sensors Ataxia-Telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication.	Journal of Virology	82	9639-9646	2008
3) Dansako H, (加藤)	A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication.	Virus Research	137	72-79	2008
4) Mori K, (加藤)	New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.	Biochemical and Biophysical Research Communications	371	104-109	2008
5) Ando M, (加藤)	Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication.	Liver International	28	1158-1166	2008
6) Hirano K, (加藤)	Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human	Liver Transplantation	14	292-298	2008

	hepatocyte cells.				
7) Nakamura M (加藤)	Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.	Journal of Medical Virology	80	632-639	2008

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, <u>Yokosuka O</u> , Taniguchi H, Nakauchi H, Iwama A..	The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.	Cancer Res	68 (19)	7742-7749	2008
Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Muroyama R, Fukai K, Imazeki F, Kawabe T, <u>Yokosuka O</u> , Omata M.	Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma.	Clin Cancer Res	14 (12)	3768-3776	2008
Inada M, <u>Yokosuka O</u> .	Current antiviral therapies for chronic hepatitis B.	Hepatol Res.	38(6)	535-542	2008
Imazeki F, <u>Yokosuka O</u> , Fukai K, Kanda T, Kojima H, Saisho H.	Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients.	Liver Int	28 (3)	355-362	2008
Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S, <u>Yokosuka O</u> .	Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B.	J Gastroenterol.	43(9)	711-719	2008
Fujiwara K, Kojima H, Yonemitsu Y, Yasui S, Imazeki F, Miki M, Suzuki K, Sakaida I, Okita K, Tanaka E, Omata M, <u>Yokosuka O</u> .	Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities.	Liver Int.	Nov 25		2008

IV. 研究成果の刊行物・別刷

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy[☆]

Masayuki Kurosaki¹, Kotaro Matsunaga¹, Itsuko Hirayama¹, Tomohiro Tanaka¹, Mitsuaki Sato¹, Nobutoshi Komatsu¹, Naoki Umeda¹, Takanori Hosokawa¹, Ken Ueda¹, Kaoru Tsuchiya¹, Hiroyuki Nakanishi¹, Jun Itakura¹, Yasuhiro Asahina¹, Shozo Miyake¹, Nobuyuki Enomoto², Namiki Izumi^{1,*}

¹Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan

²First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan

Background/Aims: Interferon (IFN) therapy leads to regression of hepatic fibrosis in chronic hepatitis C patients who achieve a sustained virologic response (SVR), while the beneficial effect is limited in those who fail to do so. The aim of the present study was to define factors associated with progression of fibrosis in patients who do not achieve a SVR.

Methods: Fibrosis staging scores were compared between paired liver biopsies before and after IFN in 97 chronic hepatitis C patients who failed therapy. The mean interval between biopsies was 5.9 years. Factors associated with progression of fibrosis were analyzed.

Results: Fibrosis progressed in 23%, remained unchanged in 47% and regressed in 29%. Steatosis and a high average alanine aminotransferase (ALT) between biopsies were independent factors for progression of fibrosis with risk ratios of 5.53 and 4.48, respectively. Incidence and yearly rate of progression of fibrosis was 64% and 0.22 ± 0.29 fibrosis units per year in those with both risk factors compared to 8% and -0.04 ± 0.17 fibrosis units per year in those negative for both factors.

Conclusions: Hepatic steatosis and elevated ALT levels are risk factors for progression of fibrosis in chronic hepatitis C patients who fail to achieve a SVR to IFN therapy and therefore may be therapeutic targets to halt the potentially progressive disease.

© 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords: Steatosis; ALT; Fibrosis

Received 20 July 2007; received in revised form 8 October 2007; accepted 17 December 2007; available online 26 February 2008

Associate Editor: J.G. McHutchison

[☆] The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufactures of the drug involved either in the past or present and they did not receive funding from the manufactures to carry out their research. They did not receive funding from any source to carry out this study.

* Corresponding author. Tel.: +81 422 32 3111; fax: +81 422 32 9551.

E-mail address: nizumi@musashino.jrc.or.jp (N. Izumi).

1. Introduction

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Mortality associated with HCV infection results from the development of liver cirrhosis and hepatocellular carcinoma, which now is the leading indication for liver transplantation [1]. Treatment with interferon (IFN), alone or in combination with ribavirin (RBV), can eradicate HCV infection in some patients, leading to sustained nor-

malization of liver function, improvement of hepatic inflammation and fibrosis and a decreased risk of the development of hepatocellular carcinoma [2,3]. The problem is that only 50% of patients achieve a sustained virological response (SVR) to therapy even with the most highly developed regimens of IFN [4,5]. The remaining patients who fail to clear the virus are left with the risk of progressive disease. In order to halt this potentially progressive disease, there is a need to establish an effective target of therapeutic intervention independent of antiviral therapy. Therefore, it is important to define risk factors for the progression of fibrosis among chronic hepatitis C patients who do not achieve a SVR to IFN therapy.

Several factors that may affect the rate of progression of fibrosis have been investigated extensively, including older age at infection, male gender, obesity, heavy alcohol consumption, and a high grade of necroinflammation [6–8]. Several cross-sectional and longitudinal studies suggest that hepatic steatosis, which is a common histological feature of chronic hepatitis C [9], influences the progression of hepatic fibrosis [10–14], while other studies did not find such an association [15–18]. Besides these conflicting results, no study to date has reported the effect of steatosis on longitudinal progression of fibrosis among patients who fail to respond to IFN therapy. Therefore, we studied factors associated with progression of fibrosis in those who failed IFN therapy by comparing paired pre-treatment and post-treatment liver biopsies.

2. Methods

2.1. Patients

The aim of the study was to identify risk factors associated with progression of fibrosis in chronic hepatitis C patients who failed to achieve a SVR to IFN therapy. To be included in this retrospective study, patients had to have undergone liver biopsy before and after therapy, been treated with IFN and not achieved a SVR. Patients with alcohol consumption of more than 20 g per day, co-infected with HBV or HIV, and those with another known aetiology of liver disease, such as autoimmune hepatitis or metabolic disorders, were excluded. A database of patients who had undergone liver biopsy at Musashino Red Cross Hospital between 1990 and 2004 was reviewed retrospectively and a total of 1241 chronic hepatitis C patients treated with IFN were identified; of these, 407 had a SVR and 834 had not achieved a SVR. Among those with treatment failure, 104 fulfilled the above criteria but seven patients with cirrhosis before treatment were excluded because the endpoint of the study was progression of fibrosis. Therefore, this study cohort consisted of 97 patients. In these patients, second liver biopsies were performed before the second course of IFN therapy. Otherwise, there were no standardized indications for the second liver biopsy which may be the limitation of our study. Demographic characteristics of patients at the time of initial biopsy are shown in Table 1. The time between the paired biopsies was 5.9 years on average, with a range of 1.2–11.6 years. The median interval between first biopsy and IFN therapy was 3 days (range 2–93 days), and that between completion of IFN therapy and second biopsy was 5.4 years (range 0.8–11.2 years). Laboratory tests were performed monthly or bimonthly in all patients and all measurements were taken at our single hospital.

Table 1
Demographic characteristics of patients

Number of patients	97
Age (years)	52 ± 9
Gender: male/female	50/47
BMI (kg/m ²)	23.9 ± 3.2 (median 24.0, range 19–33)
BMI <25/25–30/30 ≤ (kg/m ²)	55/37/5
<i>Route of transmission</i>	
Blood transfusion/unknown	38/59
Duration of infection (years)	30.4 ± 9.2 (median 33.5, range 3–48)
<i>Genotype 1b/2a/2b</i>	
Serum HCV-RNA (Meq/ml)	85/4/8
Pretreatment AST (IU/l)	7.7 ± 9.7
Pretreatment ALT (IU/l)	104 ± 69
Pretreatment GGT (IU/l)	51 ± 44
<i>Histological variables at first biopsy</i>	
Stage of fibrosis 1/2/3	33/38/26
Grade of activity 0/1/2/3	15/36/41/5
Grade of steatosis 0/1/2/3	21/37/25/14
Size of steatosis macro/micro/mixed	16/17/64
Localization of steatosis centrilobular/diffuse	3/94

BMI, body mass index; AST, aspartate aminotransferase, normal range is 7–38 IU; ALT, alanine aminotransferase, normal range is 4–43 IU/l; GGT, gamma-glutamyltransferase, normal range is 0–73 IU/l; macro, macro-vesicular steatosis; micro, micro-vesicular steatosis.

2.2. Histological evaluation

Median length of biopsy specimen and number of portal tracts were 13.0 mm (range 10–40 mm) and 12 (range 6–34). All liver biopsy specimens were evaluated separately by three independent pathologists who were blinded to the clinical data. If there was discordance, the scores assigned by two pathologists were used for the analysis. Fibrosis and activity were scored according to the METAVIR scoring system [19]. Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis: portal fibrosis without septa), F2 (moderate fibrosis: few septa), F3 (severe fibrosis: numerous septa without cirrhosis) and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of 0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity) and A3 (severe activity). Percentage of steatosis was quantified by determining the average proportion of hepatocytes affected by steatosis and was graded on a scale of 0–3: grade 0 (no steatosis), grade 1 (0–9%), grade 2 (10–29%), and grade 3 (over 30%). Size of steatosis was categorized into micro-vesicular, macro-vesicular and mixed types. Localization of steatosis was categorized into either centrilobular or diffuse pattern. Definition of changes in the grade of steatosis was as follows: worsening as 1 point or more increase, improvement as 1 point or more decrease, and stability as no change.

2.3. Changes in fibrosis-staging score overtime

Changes in progression of fibrosis were defined as follows: progression of fibrosis was defined as a 1 point or more increase, regression as a 1 point or more decrease and stability as no change in the METAVIR fibrosis-staging score. In addition, because the time between paired biopsies was variable, the yearly rate of progression of fibrosis was calculated as the change in fibrosis-staging score divided by the time between paired biopsies, as originally described by Poyndar et al. [6].

2.4. Statistical analysis

The STAT View software package was used for statistical analysis. Categorical data were analyzed using the Fisher's exact test. Continuous variables were compared with the Student's *t* test. Variables that were statistically significant in univariate analysis were included in multivariate analysis using logistic regression analysis. The Kaplan–Meier method and log-rank test were used to analyze the time to occurrence of fibrosis progression. A *p*-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Factors associated with the initial stage of fibrosis (cross-sectional study)

All three pathologists assigned the same score in 85% of patients for fibrosis staging and 95% of patients for steatosis-grading. In cases with discordance, at least two pathologists assigned the same score. The stage of fibrosis in the initial liver biopsy was F1 in 33, F2 in 38 and F3 in 26 patients. Various clinical factors were analyzed in association with the advanced stage of fibrosis. As a result, the presence of F3 fibrosis was associated with older age, (51 ± 9 in F1–2 vs. 55 ± 9 in F3, $p = 0.03$), higher grade of histological activity (A2–3 was 35% in F1–2 vs. 84% in F3, $p = 0.0001$) and higher grade of steatosis (steatosis grade 2–3 was 34% in F1–2 vs. 58% in F3, $p = 0.04$).

The grade of steatosis was 0 in 21, 1 in 37, 2 in 25 and 3 in 14 patients. A higher grade of steatosis was associated with female gender (the male/female ratio was 35/23 in grade 0–1 vs. 15/24 in grade 2–3, $p = 0.04$), increased BMI (BMI over 25 kg/m² was 31% in grade 0–1 vs. 62% in grade 2–3, $p = 0.006$), and higher grade of histological activity (A2–3 was 38% in grade 0–1 vs. 62% in grade 2–3, $p = 0.03$). Multivariate logistic regression analysis revealed that increased BMI and female gender were independent factors associated with a high grade of steatosis (Table 2).

Table 2
Multivariate logistic regression analysis of factors associated with hepatic steatosis

	Odds	95% C.I.	<i>p</i> Value
BMI			
≥25 kg/m ²	4.23	1.63–10.95	0.003
Gender			
Female	2.75	1.06–7.14	0.04
Activity grade			
2–3	2.30	0.85–6.26	0.10
Fibrosis stage			
3	1.63	0.53–4.97	0.39

3.2. Change in fibrosis-staging scores over time (longitudinal study)

Fibrosis staging progressed in 23% (progression by 2 points in 5% and 1 point in 18%), remained unchanged in 47% and regressed in 29% (regression by 2 points in 2% and 1 point in 27%). At first liver biopsy, laparoscopy was performed in 73 patients and the presence of cirrhosis (F4) was carefully excluded. In another 24 patients, the possibility of mis-diagnosis of F4 as F3 remains. However, the incidence of fibrosis progression did not differ according to the initial stage of fibrosis (21.2% in F1, 26.3% in F2 and 19.2% in F3, $p = 0.78$) which indicates that misdiagnosis of F4 as F3 at initial biopsy is unlikely.

Among various factors, as shown in Table 3, a higher grade of steatosis, higher levels of ALT and AST (average value for the period between the paired liver biopsies) were associated with progression of fibrosis. Since there was significant correlation between ALT and AST levels ($r = 0.684$, $p < 0.0001$), these two variables could not be analyzed together in multivariate analysis.

Table 3
Factors associated with the progression of fibrosis over time

	Progression <i>n</i> = 22	Non- progression <i>n</i> = 75	<i>p</i> Value
Gender: male/female	9/13	41/34	0.33
Age at biopsy: <60/≥60 years	14/8	59/16	0.17
HCV genotype: 1b/non-1b	19/3	66/9	0.99
BMI: <25/≥25 kg/m ²	11/11	44/31	0.48
Duration of infection (years)	32.1 ± 5.2	29.9 ± 10.0	0.56
<i>Activity on first biopsy</i>			
Grade: 0–1/2–3	8/14	43/32	0.10
<i>Steatosis on first biopsy</i>			
Grade: 0–1/2–3	6/16	52/23	0.001
Size: macro/micro/mixed	4/4/14	12/13/50	0.96
Location: centrilobular/diffuse	1/21	2/73	0.54
<i>Evolution of steatosis</i>			
Worsening/improvement/stable	2/2/18	9/8/58	0.09
Average ALT: <100/≥100 IU/l	13/9	67/8	0.003
Average AST: <75/≥75 IU/l	10/12	61/14	0.002
Interval between biopsies (years)	5.1 ± 3.2	6.2 ± 2.4	0.09
Interval between completion of IFN and second biopsy (years)	4.6 ± 3.2	5.7 ± 2.4	0.10
<i>Treatment regimen</i>			
RBV–/RBV+	22/0	71/4	0.27
<i>Response to IFN</i>			
Relapser/non-responder	16/6	53/22	0.99
<i>Evolution of weight</i>			
Gain/loss/stable	5/8/9	29/21/25	0.38

macro, macro-vesicular steatosis; micro, micro-vesicular steatosis; RBV–, interferon monotherapy; RBV+, interferon plus ribavirin combination therapy.

Duration of infection was determined in 38 patients whose source of infection was blood transfusion.




Fig. 1. Progression of fibrosis stage, hepatic steatosis and the average level of ALT. The progression of the fibrosis score over time is illustrated using bar charts. (a) Steatosis grades of 2 or 3 at initial liver biopsy were associated with the increased progression of fibrosis over time. (b) High average ALT levels during the observation period were associated with progression of fibrosis at the threshold of 100 IU/l.

Thus, average level of ALT was used for the following analysis. The probability of progression of fibrosis was 14%, 8%, 36% and 50% in patients with steatosis grades of 0, 1, 2 and 3, respectively ($p = 0.008$), and 17%, 17%, 13%, 21% and 53% in patients with average ALT values of <40, 40–59, 60–79, 80–99 and over 100 IU/l, respectively ($p = 0.02$) (Fig. 1). Multivariate logistic regression analysis revealed that these two were independent risk factors associated with the progression of fibrosis with risk ratios of 5.14 for steatosis ($p = 0.004$) and 5.21 for ALT ($p = 0.01$) (Table 4).

When patients were categorized in terms of these two risk factors, the incidence of progression of fibrosis was as high as 64% in those with both risk factors, compared to 8% in those negative for these factors. Conversely, the incidence of fibrosis regression was only 9% in those with both risk factors, compared to 37% in those negative for these factors ($p = 0.0003$) (Fig. 2).

In order to adjust for the effect of variable intervals between paired biopsies, the yearly rate of progression of fibrosis was calculated as the change in the fibrosis-staging score divided by the time between paired biopsies. The average of all patients was 0.02 ± 0.22 fibrosis units per year. Again, a higher grade of steatosis ($p = 0.004$) and higher average level of ALT

($p = 0.0005$) were associated with a higher rate of progression of fibrosis (Table 5). In addition, the yearly rate of progression of fibrosis was 0.22 ± 0.29 fibrosis units per year in those with both risk factors, 0.12 ± 0.37 in those with elevated ALT alone, 0.05 ± 0.16 in those with steatosis alone and -0.05 ± 0.17 in those negative for these two factors ($p = 0.001$). Time to progression of fibrosis at second biopsy was also analyzed by the Kaplan–Meier method. The cumulative probabilities of progression of fibrosis at five years were 58% in those with both risk factors, 33% in those with elevated ALT alone, 18% in those with steatosis alone and 2% in those negative for these two factors ($p < 0.0001$) (Fig. 3).

Table 4
Multivariate logistic regression analysis of factors associated with progression of fibrosis over time

	Odds	95% C.I.	<i>p</i> Value
Steatosis grade			
≥2	5.14	1.67–15.77	0.004
Average ALT			
≥100 IU/l	5.21	1.49–18.20	0.01




Fig. 2. Evolution of fibrosis stage in terms of risk factors. Patients were categorized into four groups according to the presence or absence of two risk factors. The upper bar chart (dark gray) indicates the progression of fibrosis while the lower bar chart (light gray) indicates the regression of fibrosis.

Table 5
Factors associated with the yearly rate of fibrosis progression

	n	Mean	SD	p Value
Gender				
Male	50	-0.01	0.19	0.12
Female	47	0.06	0.23	
Age at biopsy				
<60 years	73	-0.0002	0.21	0.06
≥60 years	24	0.10	0.23	
HCV genotype				
1b	83	0.02	0.20	0.37
non-1b	14	0.08	0.32	
BMI				
<25 kg/m ²	53	0.004	0.24	0.32
≥25 kg/m ²	44	0.05	0.19	
Steatosis on first biopsy				
0–1	58	-0.03	0.20	0.004
2–3	39	0.10	0.21	
Activity on first biopsy				
0–1	51	-0.001	0.21	0.24
2–3	46	0.05	0.22	
Fibrosis on first biopsy				
1–2	71	0.03	0.20	0.43
3	26	-0.01	0.25	
Average ALT between paired biopsies				
<100 IU/l	80	-0.01	0.17	0.0005
≥100 IU/l	17	0.18	0.31	

4. Discussion

In the present study, we found that a higher grade of hepatic steatosis at baseline and a higher average value of ALT are independent risk factors for the progression of fibrosis over time in chronic hepatitis C patients who fail to achieve a SVR to IFN therapy. These two factors may be involved in promoting the progression of fibrosis. The association between steatosis and progression of

fibrosis in untreated patients had been suggested by previous studies but this study is the first to demonstrate a similar association for treated patients. These findings are particularly important to establish a rationale for identifying therapeutic targets to halt potentially progressive disease independent of antiviral therapy.

There have been many studies that analyzed the association between steatosis and progression of liver fibrosis in HCV-infected patients, and the majority have shown a positive association [10–13], including a large scale meta-analysis [14]. However, some studies did not report this association [15–18]. There are two possible reasons for these conflicting results. First, longitudinal studies, rather than cross-sectional studies, are particularly important in the analysis of the role of steatosis in time-dependent progression of hepatic fibrosis, because cross-sectional studies involve patients with an unknown duration of steatosis. Three of four longitudinal studies that analyzed the progression of fibrosis through paired biopsies in untreated patients showed that the presence or worsening of steatosis was associated with the progression of fibrosis [12,13,20], and the probability of progression of fibrosis was significantly related to the grade of steatosis [13]. In one study, however, progression of fibrosis was correlated with older age, periportal necroinflammation and ALT elevations but not with steatosis [17]. Interestingly, steatosis was associated with older age, higher body mass index and ALT elevations in that study, indicating an indirect association of steatosis and fibrosis progression. The authors assumed that steatosis was the result rather than the cause of inflammation. This observation highlights the second reason for the controversies over a correlation between the presence of steatosis and progression of fibrosis, that is, there are so many confounding factors associated with both steatosis and fibrosis progression such as older age, advanced stage of fibrosis, higher degree of inflammation, elevated ALT, increased body mass index and insulin resistance. Because it is very difficult to prove a causal relationship between these confounding factors through clinical observations, steatosis may be a hallmark of the progression of fibrosis but it is unclear whether the effect of steatosis on progression of fibrosis is direct or mediated by other confounding factors.

Hepatic steatosis is a common pathological finding in patients with chronic hepatitis C [9]. Because the proportion of patients with steatosis is higher than would be expected from a chance association, a direct role of HCV in the pathogenesis of steatosis is suggested, at least in some patients with genotype 3 infection [21]. Furthermore, other observations suggest that steatosis may be metabolic; it is correlated with a high body mass index, visceral adiposity and insulin resistance, especially in non-3a genotypes and metabolic steatosis also is correlated with progression of fibrosis [11,22]. The




Fig. 3. Probability of fibrosis progression according to the presence of risk factors. Patients were categorized into four groups according to the presence or absence of two risk factors and the time to progression of fibrosis was analyzed.

most reliable evidence that metabolic steatosis is associated with progression of fibrosis is shown by a study indicating that weight reduction in patients with chronic hepatitis C leads to a reduction in steatosis and an improvement in fibrosis, despite the persistence of HCV infection. A reduction in steatosis was significantly associated with a decrease in stellate cell activation and regression of hepatic fibrosis in 56% of patients. Thus, weight reduction may provide an important new adjunct treatment strategy for patients with chronic hepatitis C [23]. A recent study showed that the administration of pioglitazone led to metabolic and histological improvement in subjects with non-alcoholic steatohepatitis [24]. Whether amelioration of insulin resistance could improve steatosis and fibrosis in chronic hepatitis C awaits future investigation.

The mechanism by which steatosis could aggravate hepatic fibrosis in chronic hepatitis C patients remains largely hypothetical. Steatosis related insulin resistance may contribute to hyperinsulinemia and increased hepatic expression of connective tissue growth factor leading to progression of fibrosis [25]. Alternatively, a steatohepatitis-like pathway may be involved where steatosis requires a second hit for progression to fibrosis [26]. The most likely candidate is an oxidative stress with subsequent lipid peroxidation which is reported to correlate with the stage of fibrosis [27]. Another important candidate is an antiviral inflammatory response. It is reported that steatotic liver has increased susceptibility to inflammatory response [28] and that a higher grade of steatosis is correlated with a higher degree of inflammation or elevated ALT [14,15,17]. Higher degree of inflammation or elevated ALTs are associated with the progression of fibrosis [29,30], but hepatic steatosis may be responsible for the amplification of hepatic inflammation and vice versa, and the coexistence of these two factors may lead to further progression of fibrosis, as in patients with non-alcoholic steatohepatitis. In our study, average value of ALT between two biopsies was associated with fibrosis progression, whereas histological inflammation at first liver biopsy was not. The reason for this discordance may be explained by the dynamic process of hepatic necroinflammation. Severity of histological inflammation at the time of biopsy may not reflect subsequent inflammation process, whereas average value of regularly determined ALT may reflect entire fluctuation of hepatic inflammation. If so, our finding may support the hypothesis that co-operation of steatosis as the first hit and dynamic process of hepatic inflammation as the second hit promotes fibrosis progression. On the other hand, elevation of ALT may not be a mere reflection of hepatic inflammation so much as hepatocellular death such as apoptosis. Since it is reported that apoptotic caspase activation is elevated in HCV-associated steatosis [31] and that steatotic liver has increased susceptibility to apoptosis [28], elevation of ALT may also reflect an

apoptosis amplified by steatosis which may lead to fibrosis progression.

Regardless of the precise mechanism, the results of the present study suggest that lowering of ALT levels may be beneficial in preventing progression of fibrosis in patients who failed to achieve a SVR. In our population, all patients received 24 weeks of IFN therapy and none received long-term maintenance therapy aiming to ameliorate hepatic inflammation. However, we speculate that amelioration of hepatic inflammation and lowering ALT levels by long-term IFN may prevent fibrosis progression in patients who remain viremic since it has been reported that IFN slowed the natural progression of fibrosis in patients who failed IFN therapy when the rate of progression of fibrosis after IFN therapy was compared to the estimated rate of progression before therapy [2,32], and that treatment duration was associated with the reduction of fibrosis independent of virological response [2]. Another possible approach to lower ALT levels may be the use of ursodeoxycholic acid, which has been reported to induce an almost 30% decrease in serum ALT levels [33,34]. The long-term efficacy of therapies targeted to the reduction of hepatic fibrosis needs future verification.

Some factors related to fibrosis progression in previous studies such as obesity [35] and worsening of steatosis [20] were not significant in our study. In our study where the majority of the population had normal body weight and very few had obesity ($BMI \geq 30 \text{ kg/m}^2$), impact of increased BMI on fibrosis progression may not be evaluated. Also, a smaller number of patients with worsening of steatosis (11.3% in present study and 34% in previous study [20]) may be the reason for the discrepancy. This may be due to difference in patient selection since no patients in that study had antiviral treatment between two biopsies.

In conclusion, the presence of hepatic steatosis and elevated ALT levels are risk factors for progression of fibrosis in chronic hepatitis C patients who failed to achieve a SVR to IFN therapy. These two factors may be a therapeutic target to halt the potentially progressive disease independent of antiviral therapy.

References

- [1] Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med* 2000;132:296–305.
- [2] Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. *Hepatology* 2000;32:1131–1137.
- [3] Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med* 1999;131:174–181.

- [4] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–965.
- [5] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–982.
- [6] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825–832.
- [7] Marcelin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;36:S47–S56.
- [8] Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C – natural history and cofactors. *Aliment Pharmacol Ther* 2005;22 Suppl 2:74–78.
- [9] Lefkowitz JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer Jr HC, et al. Pathological diagnosis of chronic hepatitis C – a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. *Gastroenterology* 1993;104:595–603.
- [10] Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 1999;29:1215–1219.
- [11] Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001;33:1358–1364.
- [12] Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol* 2002;37:837–842.
- [13] Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. *Hepatology* 2005;41:82–87.
- [14] Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006;130:1636–1642.
- [15] Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. *Gut* 2003;52:1638–1643.
- [16] Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. *Gastroenterology* 2003;125:1695–1704.
- [17] Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. *Hepatology* 2006;43:780–787.
- [18] Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology* 2007;45:80–87.
- [19] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996;24:289–293.
- [20] Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. *Gut* 2003;52:288–292.
- [21] Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. *Hepatology* 1997;25:735–739.
- [22] Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. *Gut* 2005;54:1003–1008.
- [23] Hickman JJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. *Gut* 2002;51:89–94.
- [24] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006;355:2297–2307.
- [25] Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. *Hepatology* 2001;34:738–744.
- [26] Day CP, James OF. Steatohepatitis: a tale of two “hits”? *Gastroenterology* 1998;114:842–845.
- [27] Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. *J Clin Pathol* 1997;50:401–406.
- [28] Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. *Hepatology* 2004;39:1230–1238.
- [29] Mathurin P, Moussalli J, Cadranet JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *Hepatology* 1998;27:868–872.
- [30] Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. *Gastroenterology* 2003;124:97–104.
- [31] Seidel N, Volkmann X, Langer F, Flemming P, Manns MP, Schulze-Osthoff K, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. *Hepatology* 2005;42:113–120.
- [32] Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. *Gastroenterology* 1999;117:1164–1172.
- [33] Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. *Gut* 2007;56:1747–1753.
- [34] Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. *Hepatology* 1994;20:558–564.
- [35] Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol* 2002;97:2408–2414.

Original Article

Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication *in vitro*

Haofan Jin,¹ Atsuya Yamashita,¹ Shinya Maekawa,² Pinting Yang,^{1,3} Limin He,¹ Satoru Takayanagi,¹ Takaji Wakita,⁴ Naoya Sakamoto,⁵ Nobuyuki Enomoto² and Masahiko Ito¹

¹Department of Microbiology, ²First Department of Internal Medicine, University of Yamanashi, Yamanashi, and

³Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan;

⁴Department of Rheumatology and Immunology, China Medical University, Shenyang, China; and ⁵Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan

Aim: Hepatitis C virus (HCV), which infects an estimated 170 million people worldwide, is a major cause of chronic liver disease. The current standard therapy for chronic hepatitis C is based on pegylated interferon (IFN) α in combination with ribavirin. However, the success rate remains at approximately 50%. Therefore, alternative agents are needed for the treatment of HCV infection.

Methods: Using an HCV-1b subgenomic replicon cell culture system (Huh7/Rep-Feo), we found that griseofulvin, an oral antifungal agent, suppressed HCV-RNA replication and protein expression in a dose-dependent manner. We also found that griseofulvin suppressed the replication of infectious HCV JFH-1. A combination of IFN α and griseofulvin exhibited a synergistic inhibitory effect in Huh7/Rep-Feo cells.

Results: We found that griseofulvin blocked the cell cycle at the G₂/M phase in the HCV subgenomic replicon cells, but did not inhibit HCV internal ribosome entry site-dependent translation.

Conclusion: Our results suggest that griseofulvin may represent a new approach to the development of a novel therapy for HCV infection.

Key words: cell cycle, griseofulvin, hepatitis C virus internal ribosome entry site, hepatitis C virus replicon, JFH-1

INTRODUCTION

HEPATITIS C VIRUS (HCV) is an etiologic agent of chronic liver disease,^{1,2} and it is estimated that approximately 170 million people worldwide are infected with the virus. Chronic hepatitis C can lead to severe liver diseases, including fibrosis, cirrhosis, and hepatocellular carcinoma.³ With advancements in HCV therapy, including the most recent combination of pegylated interferon (IFN) α and ribavirin, up to one-half of patients achieve a sustained virological response.

However, the remainder cannot clear the virus, demonstrating a great need for more powerful therapeutic modalities.⁴

Investigations have been hampered by the lack of an efficient HCV cell culture system. In 1999, the establishment of an HCV subgenomic replicon cell culture system improved the situation. The subgenomic replicon RNA is composed of the HCV 5' untranslated region (UTR) containing the internal ribosomal entry site (IRES), a neomycin phosphotransferase (neo) gene and the HCV non-structural (NS) proteins through 3–5B under the control of an encephalomyocarditis virus (EMCV) IRES, followed by the HCV 3' UTR.⁵ A HCV replicon carrying, in addition to the selectable marker, a gene encoding luciferase, can be used to screen a large number of compounds for antiviral activity.^{6–8} The recent development of an *in vitro* HCV infection system provides an opportunity to evaluate inhibitors of all stages of the HCV life cycle.^{9–11}

Correspondence: Dr Atsuya Yamashita, Department of Microbiology, Division of Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan. Email: atsuyay@yamanashi.ac.jp
Received 12 September 2007; revision 31 January 2008; accepted 11 February 2008.

Currently, proof of concept has been obtained in clinical trials of three different HCV NS3 protease inhibitors, BILN 2061,^{12,13} telaprevir (VX-950),¹⁴ and SCH 503034.¹⁵ However, because of many factors, including possible side-effects and the emergence of drug-resistant mutants, there is still great need for improved therapies. We focused therefore on screening a set of licensed drugs which have not been recommended previously for antiviral use. Here, we found that the oral antifungal agent, griseofulvin, had a suppressive effect on HCV replication, assessed using the HCV-1b subgenomic replicon system and the particle-producing cell culture HCV-2a model of JFH-1. The mechanism of the anti-HCV activity of griseofulvin also was studied.

METHODS

Cell cultures and HCV replicon

THE HUMAN HEPATOMA cell line, Huh7, was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin. For subgenomic replicon Huh7/Rep-Feo (HCV 1b replicon that expresses a chimeric protein consisting of neomycin phosphotransferase and firefly luciferase) cells,^{7,8} the culture medium was supplemented with 250 µg/mL G418. Huh 7.5.1/JFH-1 cells (Huh 7.5.1 chronically infected HCV JFH-1) were maintained in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin.¹⁶

Reagents

Griseofulvin and fluconazole were purchased from Wako Pure Chemical (Tokyo, Japan). Itraconazole was purchased from LKT Laboratories (St Paul, MN, USA). Recombinant human IFN α -2b was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell viability assays

For griseofulvin and fluconazole, viable cell growth was determined by a 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl) tetrazolium inner salt (MTS) reduction assay using the Cell Titer 96 aqueous one solution cell proliferation assay (Promega, Madison, WI, USA), according to the manufacturer's protocol.

For itraconazole, viable cell growth was determined using the CellTiter-Glo luminescent cell viability assay (Promega, USA), according to the manufacturer's protocol.

Luciferase activity assays

Typically, Huh7/Rep-Feo cells were seeded in a 48-well plate at a density of 2×10^4 cells per well. Compounds were added to the culture medium at various concentrations. After 72 h of culture, the expression levels of the HCV replicon were measured by luciferase assay using the luciferase assay system (Promega, USA) and the Luminescencer-JNR AB-2100 (Atto, Tokyo, Japan).

The Huh7 cells stably transfected with the pEF Fluc IN vector were mock treated (control) or treated with 20 µM or 40 µM griseofulvin. After 72 h of culture, luciferase assays were performed using the luciferase assay system and the Luminescencer-JNR AB-2100. Luciferase activity was normalized by the protein concentration, measured using a BCA protein assay kit (Pierce, Rockford, IL, USA).

The Huh7 cells stably transfected with the pEF RLuc-HCV IRES Feo vector were mock treated (control) or treated with 20 µM griseofulvin. Dual luciferase activities were carried out at 8, 16, 24, and 32 h after exposure to griseofulvin using the dual luciferase reporter assay system and the Luminescencer-JNR AB-2100.

All assays were performed in triplicate, and the results were expressed as mean \pm SD relative light units.

RNA analysis

Total cellular RNA was extracted from the Huh7/Rep-Feo cells using the RNAqueous-4PCR kit (Ambion, Austin, TX, USA). RNA was reverse transcribed with a ThermoScript reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA).

Quantitative real-time polymerase chain reaction (PCR) was carried out using ABI Prism 7500 (Applied Biosystems, Foster City, CA, USA). The forward and reverse primers for the 5' UTR of HCV-RNA were 5'-TGCGGAACCGGTGAGTACA-3' and 5'-CTTAAGGTTAGGATTCGTGCAT-3', respectively. The fluorogenic probe used for the quantification of HCV-RNA was 5'-(FAM)-CACCTATCAGGCAGTA-CCACAAGG CC-(TAMRA)-3'. Human 18S ribosomal RNA levels in the samples were analyzed by quantitative real-time PCR to normalize the RNA content. The forward and reverse primers for human 18S ribosomal RNA were 5'-ACTCTAGATAAAGCTCGGGCCGA-3' and 5'-GATGTGGTAGCCGTTTCTCAGG-3', respectively. The fluorogenic probe used for quantification of human 18S ribo-

somal RNA was 5'-(FAM)-CCATTGGAACGCTGCCCC TATCAACTTT-(TAMRA)-3'. The method has been described elsewhere.¹⁷

The primers used for reverse transcription (RT)-PCR were as follows: human 2',5'-oligoadenylate synthetase (2',5'-OAS): forward primer, 5'-CAATCAGCGAGGCC AGTAATC-3' and reverse primer, 5'-TGGTGAGAAGTGC TGGGGTC-3'; human myxovirus resistance protein A (MxA): forward primer, 5'-GTCAGGAGT-TGCCCTT CCCA-3' and reverse primer, 5'-GGCCCCCTTCCTT ACCCITA-3'; and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH): forward primer, 5'-GAAG GTGAAGGTCGGAGTC-3' and reverse primer, 5'-CTT TAGGGTGTAGGTAGAAG-3', respectively. Each reaction mixture contained cDNA (3 µL), 1.5 mM MgCl₂, 200 µM dNTP, 1 µM each primer, and 1.25 U AmpliTaq Gold (Applied Biosystems, USA) with 1× supplied reaction buffer. After activation of AmpliTaq Gold activity at 95°C for 10 min, the temperature cycling conditions for MxA were 29 cycles consisting of denaturation at 95°C for 30 s, annealing at 56°C for 1 min, and extension at 72°C for 1 min. For 2',5'-OAS, the conditions were 32 cycles consisting of denaturation at 95°C for 30 s, annealing at 53°C for 1 min, and extension at 72°C for 1 min. For GAPDH, the conditions were 30 cycles consisting of denaturation at 95°C for 30 s, annealing at 53°C for 1 min, and extension at 72°C for 1 min. PCR products were subjected to electrophoresis in a 3% agarose gel.

Western blotting

Preparation of cell lysates, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting were performed as described previously.¹⁸ The antibodies used in this study were the anti-NS3 antibody (Santa Cruz Biotechnology, USA) anti-NS5A antibody (Virogen, Watertown, MA, USA) and anti-β-actin antibody (Cell Signaling, Danvers, MA, USA). Alkaline phosphatase-conjugated secondary antibodies and CDP-Star chemiluminescent substrate (New England Biolabs, Beverly, MA, USA) were used for detection.

Cell cycle analysis

Harvested cells were washed once with phosphate-buffered saline (PBS) and fixed with 70% ethanol at 4°C for 1 h. After an additional wash, the cells were treated with 250 µg/mL RNase A at 37°C for 1 h and subsequently stained with 50 µg/mL propidium iodide at 4°C for 1 h. The DNA content was then analyzed by FACS-

Calibur (BD Biosciences, Franklin Lakes, NJ, USA) with ModFit LT software (Verity Software House, Topsham, ME, USA).

Analyses of drug synergy

The effects of the treatment of Huh7/Rep-Feo cells with griseofulvin and IFN α , alone and in combination, were analyzed with CalcuSyn, a computer program based on the method of Chou and Talalaly.¹⁹ After converting the dose-effect curves for each drug or drug combination to median-effect plots, the program calculated a combination index (CI). The CI of <1, 1, and >1 indicate synergy, an additive effect, and antagonism, respectively.

Plasmids and stable transfection

The plasmid pEF-Fluc-IN was constructed as follows. The fragment carrying the firefly luciferase was amplified from the pGL3 control vector (Promega, USA) by PCR using a pair of primers (5'-GAATTCATGGAAGAC GCCAAAACATAAA-3' [*EcoRI* site] and 5'-GCGGC CGCTTACACGGCGATCCTTCCGCC-3' [*NotI* site]). The PCR product was cloned into the pGEM-T Easy vector (Promega, USA). The EMCV IRES Neo fragment was excised from the pMXs-IN vector by *NotI* and *Sall* digestion.²⁰ The *EcoRI-Sall* fragment of the pCHO vector was excised from the pGag-pol-IRES-bs' vector by *EcoRI* and *Sall* digestion.²¹ To construct pEF-Fluc-IB, the *EcoRI-NotI* fragment of firefly luciferase, and the *NotI-Sall* fragment of the EMCV IRES Neo were inserted into the *EcoRI* and the *Sall* site of pCHO by triple ligation.

The plasmid pEF Rluc-HCV IRES Feo was constructed as follows. The fragment carrying the Renilla luciferase was amplified from the pHRL-TK vector (Promega, USA) by PCR using a pair of primers (5'-GAAATCATGGCT TCCAAGGTGTACGACCC-3' [*EcoRI* site] and 5'-GGAT CCTTACTGCTCGTCTTCCAGCACGC-3' [*BamHI* site]). The fragment carrying the HCV IRES Feo was amplified from the pRep-Feo vector⁷ by PCR using a pair of primers (5'-GGATCCGCCAGCCCCGATTGGGGGCG AC-3' [*BamHI* site] and 5'-GTGACTCAGAAGAAC TCGTCAAGAAGGC-3' [*Sall* site]). Each PCR product was cloned into the pGEM-T Easy vector. To construct pEF Rluc-HCV IRES Feo, the *EcoRI-BamHI* fragment of Renilla luciferase, and the *BamHI-Sall* fragment of HCV IRES Feo were inserted into the *EcoRI* and *Sall* site of pCHO by triple ligation.

The pEF-Fluc-IB and pEF Rluc-HCV IRES Feo was transfected into Huh7 cells using Effectene transfection reagent (QIAGEN, Hilden, Germany), according to the manufacturer's recommendation. Two days after trans-

fection, the Huh7 cells were selected in a medium containing 250 µg/mL G418.

Immunofluorescent staining

After treatment with griseofulvin for 72 h, HCV JFH-1-infected cells were fixed with cold methanol and blocked using Blocking One (Nacalai Tesque, Kyoto, Japan). For the detection of the NS3 protein, the cells were incubated with the anti-NS3 antibody (Virogen, USA) for 1 h at room temperature. After washing with PBS, the cells were incubated with an Alexa Fluor 488 goat antimouse immunoglobulin G antibody (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. After washing with PBS, the cells were stained with 7-aminoactinomycin D for nuclear counterstaining, and analyzed using fluorescence microscopy.

RESULTS

Replication of a subgenomic HCV-1b replicon is suppressed by griseofulvin

WE INVESTIGATED THE anti-HCV effect and cell toxicity of griseofulvin in the HCV subgenomic replicon cells, Huh7/Rep-Feo. The luciferase activities of the Huh7/Rep-Feo cells showed that replication of the HCV replicon was suppressed by griseofulvin in a dose-dependent manner (Fig. 1a). Next, we performed a time-course experiment in which the luciferase activities of Huh7/Rep-Feo cells were measured at various time points after treatment with griseofulvin. As shown in Figure 1b, griseofulvin induced a decrease in the luciferase activities of Huh7/Rep-Feo cells over time. The treatment with griseofulvin had little effect on cellular viability at this range of concentration, as revealed by the MTS assay (Fig. 1c). The 50% effective concentration (EC_{50}) of griseofulvin was $6.13 \pm 0.17 \mu\text{M}$. The 50% cytotoxic concentration of this compound (CC_{50}) was $217.93 \pm 3.49 \mu\text{M}$. Thus the selectivity index (ratio of CC_{50} to EC_{50}) was 35.5 (Table 1). Furthermore, we examined the effect of other antifungal agents, fluconazole and itraconazole, on HCV-RNA replication. In contrast, fluconazole and itraconazole had little effect on HCV-RNA replication (Table 1).

We analyzed HCV-RNA levels in Huh7/Rep-Feo cells treated or not treated with griseofulvin using real-time RT-PCR. As shown in Figure 2a, treatment with griseofulvin decreased the replicon RNA titer in a dose-dependent manner. Similar results were seen at the protein level by monitoring the HCV non-structural proteins NS3 and NS5A. The Western blot analysis demon-




Figure 1 Inhibition of hepatitis C virus replication in Huh7/Rep-Feo cells by griseofulvin. (a) Huh7/Rep-Feo cells were cultured with various concentrations of griseofulvin in the medium and luciferase assays were performed after 72 h of culture. Luciferase assays were performed in triplicate. Error bars indicate mean \pm standard deviation. (b) Huh7/Rep-Feo cells were treated with various concentrations of griseofulvin (2.5–40.0 µM). Luciferase activity was measured at the time points indicated after exposure to griseofulvin. (c) 5-(3-Carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl) tetrazolium inner salt of Huh7/Rep-Feo cells cultured with the concentration of griseofulvin indicated.

Table 1 Antihepatitis C virus activities of oral antifungal agents in Huh7/Rep-Feo cells†

	EC ₅₀ (μ M)	CC ₅₀ (μ M)	SI
Griseofulvin	6.13 \pm 0.17	217.93 \pm 3.49	35.5
Fluconazole	135.6 \pm 1.25	159.06 \pm 1.07	1.2
Itraconazole	1.24 \pm 0.21	3.35 \pm 0.17	2.7

†All data represent means \pm standard deviation for three separate experiments. CC₅₀, 50% cytotoxicity concentration based on the reduction of cell viability; EC₅₀, 50% effective concentration based on the inhibition of HCV replication; SI, selectivity index (CC₅₀/EC₅₀).

stated that griseofulvin treatment results in reduced levels of these viral proteins (Fig. 2b).

However, it remains to be clarified whether the griseofulvin inhibits firefly luciferase directly. To investigate this possibility, we examined the effect of griseofulvin on firefly luciferase activity using Huh7 cells expressing firefly luciferase constitutively. The treatment of these cells with griseofulvin resulted in no significant change in the firefly luciferase activity (Fig. 3). This result excludes the possibility that griseofulvin inhibits firefly luciferase activity directly.

Anti-HCV activity of griseofulvin is not mediated by the IFN signaling pathway

It has been reported that the HCV replicon is highly sensitive to IFN.^{22,23} To determine whether the action of griseofulvin on the HCV subgenomic replicon involves the activation of IFN-stimulated gene responses, we analyzed the expression of IFN inducible genes in HCV replicon cells. The RT-PCR analysis showed that the messenger RNA for MxA and 2',5'-OAS, which are both IFN inducible genes, were induced by IFN α -2b, but not by griseofulvin (Fig. 4). These results suggest that the action of griseofulvin on the intracellular replication of HCV replicon is independent of the IFN signaling pathway.

Synergistic inhibitory effect of griseofulvin and IFN α on HCV replicon

Whether a combination of griseofulvin and IFN α exhibits a synergistic, additive, or antagonistic effect was assessed using an isobologram method.¹⁹ An isobologram analysis is an approach used in preclinical studies to quantify the extent of synergistic, additive, or antagonistic effects between drugs used in combination. For instance, a representation of an isobologram to evaluate a drug–drug interaction is shown in Figure 5a. It is

understood that synergy, additivity, and antagonism are represented by concave, linear, and convex isoeffective curves (isoboles), respectively. The combined anti-HCV effects of griseofulvin and IFN α were evaluated. Prior to the combination experiments, the optimal concentration ratio of two compounds (combination ratio) had to be determined. After preliminary experiments, three different ratios were chosen for each combination




Figure 2 Suppressive effect of griseofulvin for hepatitis C virus (HCV) replicon was confirmed by real-time reverse transcription–polymerase chain reaction (RT-PCR) and Western blot analysis. (a) Incubation of Huh7/Rep-Feo cells with griseofulvin for 72 h resulted in dose-dependent antiviral effects. Real-time RT-PCR was performed on the extracted RNA. HCV-RNA levels are shown as relative percentages of untreated control. Error bars indicate mean \pm SD. (b) Western blot analyses of NS3 and NS5A protein expressions were performed on protein extracts from cells that were treated for 72 h with varying dose of griseofulvin. β -Actin was used as a loading control.




Figure 3 No inhibition of firefly luciferase activity by griseofulvin. pEF Fluc IN vector was stably transfected into Huh7 cells. Cells were cultured without (control) and with 20 μM or 40 μM griseofulvin for 72 h. Firefly luciferase assay was performed. Luciferase activity was normalized by the protein concentration. Error bars indicate mean ± SD.




Figure 4 Griseofulvin elicited an interferon (IFN) response. Huh7/Rep-Feo cells were treated without (lane 1) or with 1, 10, or 100 U/mL IFNα-2b (lanes 2-4), and 20 (lane 5) or 80 μM griseofulvin (lane 6) for 72 h. Messenger RNA of human myxovirus resistance protein A (MxA), 2',5'-oligoadenylate synthetase (2',5'-OAS), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control were detected by reverse transcription-polymerase chain reaction analysis.





Figure 5 Effect of a combination of griseofulvin and interferon (IFN)α on intracellular hepatitis C virus (HCV)-RNA replication. (a) Representative isobologram for analyzing the interaction between two drugs. (b) Isobole plot of 50% inhibition of HCV-RNA replication. Huh7/Rep-Feo cells were treated with griseofulvin in combination with IFNα, and a luciferase assay was performed after 72 h of culture to obtain each isobole plot. Dotted line indicates an additive effect in the isobologram method used.